---
layout: default
title: Pembrolizumab
parent: 僅模型預測 (L5)
nav_order: 763
evidence_level: L5
indication_count: 10
---

# Pembrolizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Pembrolizumab: From Approved Oncology Indications to Gingival Fibromatosis

## One-Sentence Summary

Pembrolizumab is an anti-PD-1 immune checkpoint inhibitor whose approved oncology use (e.g., non-small cell lung cancer, melanoma) is documented in the literature attached to this evidence pack, though structured original-indication and mechanism-of-action data were not returned for this evaluation.
The TxGNN model predicts it may be effective for **Gingival Fibromatosis (fibromatosis, gingival)**, with a prediction score of 99.40%, but **zero clinical trials** and **zero publications** currently support this specific direction.
The evidence pack's own mechanistic assessment concludes this candidate has **no known mechanistic link** to PD-1/PD-L1 biology and is likely a model embedding-similarity artifact rather than a real signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no Singapore license records exist for this drug; other literature in this pack references established oncology use (e.g., NSCLC, melanoma) but no structured original-indication field was returned |
| Predicted New Indication | Gingival Fibromatosis |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| Singapore Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for pembrolizumab was not returned in this evidence pack (flagged as a High-severity data gap). Based on the literature attached to other candidates within this same evidence pack, pembrolizumab is known to be a humanized monoclonal antibody blocking the PD-1 receptor, restoring T-cell antitumor activity, and is used in multiple approved advanced malignancies (e.g., NSCLC per KEYNOTE-010/024, melanoma).

Gingival fibromatosis, however, is a benign fibrous gum-tissue overgrowth condition, not a malignancy, and has no established connection to immune checkpoint biology, tumor immune evasion, or PD-L1 expression. The evidence pack's own repurposing rationale is explicit on this point: there is "no known association with the PD-1/PD-L1 immune checkpoint mechanism, only a TxGNN embedding similarity score, with no clinical or literature support whatsoever."

In other words, the high numerical score (99.40%) reflects graph-embedding similarity in the knowledge graph, not a biologically grounded hypothesis. This is a case where the model's confidence score and the actual evidentiary/mechanistic support diverge sharply, which is exactly why the evidence level is capped at L5 and the decision stage remains at S0 (pre-screening, not yet advanced).

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Singapore Market Information

Pembrolizumab is not currently registered or marketed in Singapore under this evidence pack's regulatory data (0 licenses on file), so no product/authorization table can be produced.

---

## Cytotoxicity

*(Included because pembrolizumab is an antineoplastic agent based on its documented immunotherapy use elsewhere in this evidence pack — not because of the gingival fibromatosis candidate itself, which is not a malignancy.)*

| Item | Content |
|------|------|
| Cytotoxicity Classification | Immunotherapy (anti-PD-1 immune checkpoint inhibitor) — not a conventional cytotoxic agent |
| Myelosuppression Risk | Low — checkpoint inhibitors are not classically myelosuppressive; their dominant toxicity pattern is immune-related adverse events (irAEs) rather than bone marrow suppression |
| Emetogenicity Classification | Low |
| Monitoring Items | Thyroid function, liver function tests, renal function, skin and GI symptoms, and other endocrine/immune-related adverse event surveillance (per irAE-management literature referenced elsewhere in this evidence pack) |
| Handling Protection | Standard biologic IV-infusion precautions; not subject to conventional cytotoxic hazardous-drug handling protocols |

Please refer to the package insert warnings and precautions for definitive toxicity grading, as detailed DrugBank toxicity data was not returned for this query.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (Gingival Fibromatosis) has no supporting clinical trials or literature, and the evidence pack's own mechanistic review states there is no known biological link between this benign condition and the PD-1/PD-L1 pathway. This is best explained as a knowledge-graph similarity artifact rather than a genuine repurposing signal, so no forward action is warranted on this candidate.

**To proceed, the following is needed:**
- Resolve the Blocking data gap: TFDA/HSA package insert warnings and contraindications (currently unavailable, blocks any safety pre-screening)
- Resolve the High-severity data gap: mechanism-of-action data via DrugBank API (needed for any mechanistic relevance analysis)
- If further repurposing work on this drug is desired, prioritize other candidates already screened in this same evidence pack that carry stronger mechanistic and evidentiary alignment — notably rank 4, "lung hilum carcinoma" (L4 evidence level, staged at S1/"Research Question"), which is mechanistically consistent with pembrolizumab's already-established NSCLC activity, rather than rank 1 evaluated here
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

